NEW YORK, May 1 (Reuters) - Patients taking Pfizer Inc’s (PFE.N) Lyrica experienced a significant reduction in pain from the chronic condition fibromyalgia, compared with those taking a placebo in a clinical trial, the drugmaker said on Tuesday.
Pfizer said it submitted data from the study to U.S. health regulators in an effort to broaden the fast-growing drug’s approved uses to include treatment of fibromyalgia.
There are currently no medications specifically approved for fibromyalgia, a sometimes debilitating disorder with symptoms that can include intense pain, fatigue, stiffness and depression. Its cause is unknown.
Lyrica, which is currently approved to treat neuropathic pain and epilepsy seizures, saw sales more than double in the first quarter to $395 million.
Pfizer said the results from the 14-week, 745-patient study equate to a patient’s severe pain being reduced to a moderate to mild pain.
The study tested Lyrica at three doses — 600 milligrams a day, 450 mg and 300 mg — against a placebo and had patients measure their pain on a scale of zero to 10.
Thirty percent of patients taking the 600 mg dose of Lyrica said their pain was reduced by half or better compared with 27 percent at 450 mg and 24 percent at the lowest dose. Of those taking a placebo, 15 percent reported pain reduction of 50 percent or greater, Pfizer said.
Data from the study were presented at the American Academy of Neurology annual meeting in Boston.